Document:

Exhibit 10.2

                                License Agreement

     This Agreement is made and entered into between individuals Dr. Waldemar
Gottardi, Dr. Markus Nagl and Dr. Andreas Neher, Institute for Hygiene and
Social Medicine, Leopold-Franzens-Universitat, Fritz-Pregl-Stra e 3, A-6010
Innsbruck, Austria ("LICENSORS") and Atlantic Technology Ventures, Inc., a
Delaware Corporation ("LICENSEE"), having offices at 350 Fifth Avenue, Suite
5507, New York, NY 10118.

     Whereas, LICENSORS are the owners of the entire right, title and interest
in the Patents and/or Patent Applications described in Exhibit A attached
hereto, and the Technology described and/or claimed therein; and

     Whereas, LICENSEE is desirous of obtaining an exclusive worldwide license
in order to practice the above referenced Technology covered by said Patent
Rights and to manufacture, have manufactured, use and sell in the commercial
market the products made in accordance therewith; and

     Whereas, LICENSORS are desirous of granting such a license to LICENSEE in
accordance with the terms of this Agreement.

     Now, therefore, in consideration of the foregoing and the mutual agreements
contained herein, the parties agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS

     1.1     "Patent Rights" shall mean (i) the Patents and Patent Applications
described in Exhibit A attached hereto, the Technology described and/or claimed
therein, and any substitutions, divisions, continuations, continuations-in-part,
patents issuing thereon or reissues or re-examinations thereof and any and all
patents and patent applications corresponding thereto; (ii) all patents and
patent applications to the extent assigned to LICENSORS and to the extent
LICENSORS are able, under their obligations to third parties, to grant rights to
LICENSEE and on which Inventors are a named inventor, the Technology described
and/or claimed therein and any substitutions, divisions, continuations,
continuations-in-part, patents issuing thereon or reissues or re-examinations
thereof, which relate to the design, development and/or manufacture of any
products incorporating the Technology and any and all patents and patent
applications corresponding thereto; (iii) all patents and patent applications to
the extent assigned to LICENSORS and to the extent LICENSORS are able, under
their obligations to third parties, to grant rights to LICENSEE and on which
Inventors are a named inventor, the Technology described and/or claimed therein
and any substitutions divisions, continuations, continuations-in-part, patents
issuing thereon or reissues or re-examinations thereof which relate to any
improvements in the Technology and any and all patents and patent applications
corresponding thereto.  The patents and patent applications corresponding
thereto referred to in (i), (ii) and (iii) above, when filed or issued, will be
automatically incorporated in and added to this Agreement and shall periodically
be added to Appendix A attached to this Agreement and made a part hereof;
provided, however, that failure to periodically add such patents and/or patent
applications thereto shall not be considered to exclude such patents and/or
patent applications from the meaning of "Patent Rights."

<PAGE>

     1.2 "Licensed Processes" shall mean all technologies, methods, formulas,
plans or processes and any improvements thereof, relating to or which are
covered in whole or in part by any claim contained in the Patent Rights.

     1.3 "Licensed Products" shall mean products or components thereof claimed
in Patent Rights or products or components thereof made in accordance with or by
means of any Licensed Process.

     1.4 "Net Sales" shall mean the amount billed or invoiced on sales of
Licensed Products or Licensed Processes less:

     (a)  Customary trade, quantity or cash discounts and non-affiliated
          brokers' or agents' commissions actually allowed and taken;

     (b)  Amounts repaid or credited by reason of rejections or return;

     (c)  Transportation, insurance, brokerage and handling charges paid or
          reimbursed by LICENSEE or its Affiliates;

     (d)  Amounts withheld by governments;

     (e)  Tariffs, import/export duties, sales, use, value added and other
          excise or turnover taxes and other governmental charges imposed on the
          sale of Licensed Products or Licensed Processes, the provision of
          services using Licensed Products or Licensed Processes, or on the
          production, importation and/or exportation, use or distribution of
          Licensed Products or Licensed Processes;

     (f)  Sales commissions, exportation, use or distribution; and/or

     (g)  Bad debt deductions actually written off during the period.

                                        2
<PAGE>

Net Sales shall not include amounts paid or sales between or among LICENSEE
and/or its Affiliates.  In the event of a use or sale of Licensed Products or
Licensed Processes solely for clinical testing or research and development
purposes for which LICENSEE receives no revenue, the no royalty shall be due or
payable to LICENSORS pursuant to Article 3 hereof or otherwise.

     1.5     "Affiliates" shall mean any company, corporation, or business of
which LICENSEE owns or controls at least fifty percent (50%) of the voting stock
or which owns or controls at least fifty percent (50%) of the voting stock of
LICENSEE.

     1.6     "Field" shall mean all potential fields of use of the Patent Right,
the Licensed Products, and the Licensed Processes.

     1.7     "Sublicensee" shall mean an entity which LICENSEE has granted (a)
the right to manufacture and market the Licensed Products, (b) the right to
practice the Licensed Processes, or (c) the right to sublicense the Licensed
Processes to others.

     1.8     "Technology" shall mean any novel therapeutic use or formulation of
N-Chlorotaruine and any of its derivatives or analogs.

                                    ARTICLE 2

                                      GRANT

     2.1     LICENSORS hereby grant to LICENSEE and LICENSEE accepts, subject to
the terms and conditions hereof, a worldwide exclusive (event against LICENSORS)
license in the Field, under the Patent Rights, to make and have made, to use and
have used, to sell and have sold, to distribute and have distributed, and to
market and have marketed the Licensed Products, and to practice the Licensed
Processes, for the life of the Patent Rights.  Such license shall include the
right to grant sublicenses.  LICENSORS agree they will not assign, encumber,
grant a license to and/or permit a lien to exist upon, the Patent Rights in any
territory for any Field to or by any third party and will not themselves
practice the Patent Rights other than for their own non-commercial research
purposes.  Licensors agree, on behalf of themselves, their successors and any
other person or entity who or which may claim a right in or under the Patent
Rights, that any purported transfer or encumbrance of rights shall be null and
void and of no effect.

     2.2     LICENSORS hereby grant to LICENSEE the right to extend the licenses
granted in paragraph 2.1 to one or more Affiliates, subject to the terms and
conditions hereof.

                                        3
<PAGE>

     2.3     LICENSORS hereby represent and warrant to LICENSEE that LICENSORS
are the sole owners of the Patent Rights as reflected on Exhibit A on the date
hereof, no person or entity has or will have any rights of any kind with respect
to such Patent Rights except for the rights of LICENSEE pursuant to this
Agreement, and accordingly, LICENSORS have full legal right to grant to LICENSEE
the license provided for herein, and such grant does not and will not violate or
conflict with the rights of any person or entity.

                                    ARTICLE 3

                               ROYALTIES AND FEES

     3.1     LICENSEE shall pay to LICENSORS jointly and severally, during the
term of the license of paragraph 2.1, a total royalty of four percent (4%) of
the Net Sales of all Licensed Products sold by LICENSEE and its Affiliates.
LICENSEE shall pay to LICENSORS jointly and severally, during the term of the
license of paragraph 2.1, a total royalty of twenty percent (20%) of the
royalties which LICENSEE and its Affiliates receive from Sublicensees for
sublicenses of the Licensed Products or Licensed Processes.  No multiple
royalties shall be due because the sale or sublicense of any Licensed Product or
Licensed Process is described in more than one sentence of this section 3.1.  In
the event of any such overlap, the sentence which most accurately describes the
relevant transaction at issue shall prevail.  On Net Sales or sublicenses
between LICENSEE and its Affiliates, royalties shall be payable only on the
resale or resublicense by such Affiliate.

     3.2     As further consideration for the license and other rights granted
to LICENSEE hereunder, (a) LICENSEE shall pay to LICENSORS jointly and severally
a one-time patent issue fee of One Hundred Thousand Dollars ($100,000) payable
in cash or registered stock of the Licensee, (b) LICENSEE shall pay to LICENSORS
jointly and severally a one-time milestone payment of Two Hundred and Fifty
Thousand Dollars ($250,000) payable in cash or registered stock of the LICENSEE
upon successful completion of a Phase III clinical trial for a licensed Products
or Licensed Processes, and  (c) LICENSEE shall pay to LICENSORS jointly and
severally a one-time milestone payment of One Million Dollars ($1,000,000)
payable in cash or registered stock of the Licensee upon receiving new drug
approval for Licensed Products or Licensed Processes.

                                        4
<PAGE>

                                    ARTICLE 4

                                    REPORTING

     4.1     LICENSEE shall report to LICENSORS the date of first sale of
Licensed Products (or results of Licensed Processes) in each country within
thirty (30) day of occurrence.

     4.2     LICENSEE shall provide LICENSORS within sixty (60) days after each
of the calendar half-years ending June 30 and December 31, reports setting
forth, for the preceding six (6) -month period, the amount of Licensed Products
sold by LICENSEE and its Affiliates in each country, the Net Sales thereof, the
amount of Sublicensee royalties received by LICENSEE and its Affiliates and the
amount of royalty due to LICENSORS with respect to the foregoing.  With each
such royalty report, LICENSEE shall include the payment of the royalty due.
Such report shall include a detailed listing of all deductions from Net Sales,
sublicensee income, or royalties as specified herein.  If no royalties are due
to LICNESORS for any reporting period, then no written report shall be required.
All royalties due hereunder shall be payable in United States dollars.
Conversion of foreign currency to U.S. dollars shall be made at the conversion
rate existing in the United States, as quoted in The Wall Street Journal, three
(3) days prior to the date that such royalty payments by LICENSEE was due to
LICENSOR.  Payments which are more than thirty (30) days past due and which are
not the subject of a good faith controversy between the parties hereto shall be
subject to an interest charge of one percent (1%) per month.

     4.3     LICENSORS agree that at all times, both during the term and after
the termination of this Agreement, they will keep in confidence and trust all
information provided to it hereunder by LICENSEE or provided to them by any
third party pursuant to Section 5.1 hereof (the "Proprietary Information"), and
it will not use or disclose any Proprietary Information or anything directly
relating to such Proprietary Information without the written consent of the
LICENSEE. LICENSORS acknowledge that the Proprietary Information constitutes a
unique and valuable asset of the LICENSEE, which is secret and confidential and
which will be communicated to LICENSORS in confidence and that any disclosure or
other use of the Proprietary Information other than for the sole benefit of the
LICENSEE would be wrongful and would cause irreparable harm to the LICENSEE.

                                    ARTICLE 6

                          PATENT FILING AND MAINTENANCE

                                        5
<PAGE>

     6.1     LICENSEE shall take responsibility for the preparation, filing,
prosecution and maintenance of any all patent applications and patents included
in Patent Rights and shall use his best efforts to promptly procure the broadest
possible patents in all countries designated by LICENSEE pursuant to Section
6.2.

     6.2     Without limiting the provisions of Section 6.1, LICENSORS and
LICENSEE shall cooperate fully in the preparation, filing, prosecution and
maintenance of the Patent Rights including without limitations, the execution of
all papers and instruments necessary or desirable to enable LICENSEE to apply
for, to prosecute and to maintain patent applications and patents in LICENSORS'
name in any country.  Each party shall provide to the other prompt notice as to
all matters which come to its attention and which may affect the preparation,
filing, prosecution or maintenance of any such patent applications or patents.
Either party may give notice to the other of any country in which such party
wishes to seek patent protections for all or any part of the Patent Rights.  In
the case of such a designation by LICENSEE (and the provision of reasonable
assurance of payment by it of the expenses to be incurred) LICENSORS may not
refuse to seek such patent protection in the country so designated.

                                    ARTICLE 7

                                  INFRINGEMENT

     7.1     With respect to any Patent Rights, LICENSEE and/or its Sublicensees
shall have the right to prosecute in their own names and at their own expense
any infringement thereof.  LICENSORS agree to notify LICENSEE promptly of each
infringement of the Patent Rights of which LICENSORS are or become aware.
Failure by either party to commence an action which is contemplated by this
Section 7.1 shall not constitute a breach of this Agreement.

     7.2     If LICENSEE or its Sublicensee elects to commence an action as
described above or if an action is third party, LICENSORS shall have the right
either to join the action as a co-plaintiff or co-defendant or to assign to
LICENSEE all of LICENSOR's right, title and interest, expressly including the
right to sue for past infringement thereof, in each patent which is a part of
the Patent Rights and is the subject of such action.  In the event LICENSORS
join the action as a co-plaintiff, LICENSEE shall nevertheless control the
action provided that LICENSEE will endeavor to consult with LICENSORS as to the
prosecution of such action.  In the event that LICENSORS make an assignment of
such patent, such assignment shall be irrevocable, and such action on that
patent or patents shall thereafter be brought or continued without LICENSOR as a
parties, unless LICENSORS are legally indispensable parties.  Notwithstanding
any such assignment to LICENSEE by LICENSORS and regardless of whether LICENSORS
are or are not indispensable parties, LICENSORS shall cooperate fully with
LICENSEE, at LICENSEE'S expense, in connection with any action commenced by
LICENSEE or any sublicensee.  In the event that any patent is assigned to
LICENSEE by LICENSORS pursuant to this paragraph, LICENSEE shall continue to
meet its obligations under this Agreement, including without limitation its
obligation to pay royalties, as if the assigned patent or patent application
were still licensed to LICENSEE.

                                        6
<PAGE>

     7.3     If  LICENSEE or its Sublicensee elects to commence an action as
described above, LICENSEE may cover the costs and expensed of such action
(including reasonable attorneys fees and including the coverage of LICENSORS'
costs) by reducing the royalty due to LICENSOR hereunder by up to fifty percent
(50%).  In the event that such fifty percent (50%) costs and expenses exceed the
amount of royalties reduced by LICENSEE for any calendar year, LICENSEE may to
that extent reduce the royalties due to LICENSORS from LICENSEE in succeeding
calendar years, but never by more than fifty percent (50%) of the royalty due in
any one calendar year.

     7.4     Recoveries or reimbursements from such action (regardless of
whether LICENSEE or LICENSORS receive the award) shall first be applied to
reimburse LICENSEE and LICENSORS for litigation costs not paid from royalties
(if any) and then to reimburse LICENSORS for royalties withheld. Any remaining
recoveries or reimbursements shall be paid to LICENSEE.

     7.5     In the event that LICENSEE and its Sublicensee, if any, elect not
to exercise their right to prosecute an infringement of the Patent Rights
pursuant to the above paragraphs, LICENSORS may do so at their own expense,
controlling such action and retaining all recoveries therefrom.

                                    ARTICLE 8

                            TERMINATION OF AGREEMENT

     8.1     This Agreement, unless extended or terminated as provided herein,
shall remain in effect until the last to expire patent in the Patent Rights;
provided, however, that LICENSEE'S obligation to pay royalties pursuant to
--------  -------
Section 3.1 will terminate as to any Licensed Products or Licensed Processes
when the Patent Rights to which they relate expire or are abandoned.

     8.2     (a) The following events shall constitute an event of default under
this Agreement (an "Event of Default"):

          (i) LICENSEE shall become more than sixty (60) days in arrears in
     payment of royalties or expenses due pursuant to this AGREEMENT which are
     not the subject of a bona fide dispute between LICENSORS and LICENSEE and
     which have not been paid within forty five (45) days after LICENSEE has
     received notice of such arrearage from LICENSORS; or

                                        7
<PAGE>

          (ii) LICENSEE breaches this Agreement in any material respect (other
     than a breach covered by paragraph 8.2 (a) (i)) and does not cure such
     breach within sixty (60) days after written notice thereof from LICENSORS
     or, with respect to any breach incapable of being fully cured within such
     sixty (60) day period, has not made substantial good faith efforts to cure
     any such breach within thirty (30) days after written notice thereof from
     LICENSORS;

     (b)     LICENSEE may, at its option, terminate this Agreement at any time
for any reason whatsoever by doing all of the following:

          (i) Cease making, having made, using and selling any Licensed Products
     or Licensed Processes; and

          (ii) Revoke all sublicenses causing all sublicensees to cease making,
     having made, using and selling Licensed Products or Licensed Processes; and
     (iii) Give notice to LICENSORS of such cessation and of LICENSEE'S election
     to terminate; and

          (iv) Tender payment of all accrued royalties.

     8.3     On the occurrence of an Event of Default, and if such Event of
Default has not been remedied within sixty (60) days after notice in writing of
such Event of Default has been given to the LICENSEE by LICENSORS, LICENSORS may
terminate this Agreement by written notice.

     8.4     Any sublicenses granted by LICENSEE under this Agreement shall
provide for termination or assignment to LICENSORS, at the option of LICENSORS,
of LICENSEE'S interest therein upon termination of this Agreement.

                                    ARTICLE 9

                                   ASSIGNMENT

     9.1     This Agreement, the Patent Rights and the other rights and duties
appertaining hereto may not be assigned by either party without first obtaining
the written consent of the other which shall not otherwise be unreasonably
withheld. Any such purported assignment, without the written consent of the
other party, shall be null and void and of no effect. Notwithstanding the
foregoing, LICENSEE may assign this Agreement (i) to a purchaser, merging or
consolidating corporation, or acquirer of substantially all of LICENSEE'S assets
or business and/or pursuant to any reorganization qualifying under section 368
of the Internal Revenue Code of 1986 as amended, as may be in effect at such
time, or (ii) to an Affiliate of LICENSEE.

                                        8
<PAGE>

                                   ARTICLE 10

                                     GENERAL

     10.1     LICENSORS represent and warrant that they own the entire right,
title, and interest in the patent applications or patents comprising the Patent
Rights and that LICNESORS have the authority to issue licenses under said Patent
Rights. LICENSORS do not warrant the validity of the Patent Rights licensed
hereunder and make no representations whatsoever with regard to the scope of the
licensed Patent Rights or that such Patent Rights may be exploited by LICENSEE,
an Affiliate, or Sublicensee without infringing other patents provided, however,
that LICNESORS have no reason to believe that the Patent Rights are invalid or
that exploitation by LICENSEE, an Affiliate or Sublicensee of the Patent Rights
will infringe other patents.

     10.2     LICENSORS EXPRESSLY DISCLAIM ANY AND ALL IMPLIED OR EXPRESS
WARRANTIES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS OF THE TECHNOLOGY, LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED
BY THIS AGREEMENT FOR ANY PURPOSE.

     10.3  (a)     LICENSEE shall indemnify, defend and hold harmless LICENSORS
and their heirs and assigns (the "Indemnitees"), against any liability, damage,
loss or expenses (including reasonable attorney's fees and expenses of
litigation) incurred by or imposed upon the Indemnitees or any one of them in
connection with claims, suits, actions, demands or judgments arising out of any
theory of product liability (including, but not limited to, actions in the from
of tort, warranty, or strict liability) concerning any product, process or
service made, used or sold pursuant to any right or license granted under this
Agreement.  The above indemnification shall apply whether or not such liability,
damage, loss or expense is attributable to the negligent activities of the
Indemnitees but shall not apply if such liability, damage, loss or expense is
attributable to the willful misconduct of any Indemnitee.

     (b)     LICENSEE agrees, at its own expense, to provide attorneys
reasonably acceptable to LICENSORS to defend against any actions brought or
filed against any party indemnified hereunder with respect to the subject of
indemnity contained herein, whether or not such actions are rightfully brought.

                                        9
<PAGE>

     10.4     The interpretation and application of the provisions of this
Agreement shall be governed by the laws of the State of New York, in the United
States of America without regard to principles of conflicts of law.

     10.5     LICENSEE  agrees  to  comply with all  applicable  laws and
regulations. In particular, it is understood and acknowledged that the transfer
of certain commodities and technical data is subject to United States laws and
regulations controlling the export of such commodities and technical data,
including all Export Administration Regulations of the United States Department
of Commerce. These laws and regulations, among other things, prohibit or require
a license for the export of certain types of technical data to certain specified
countries. LICENSEE hereby agrees and gives written assurance that it will
comply with all United States laws and regulations controlling the export of
commodities and technical data, that it will be solely responsible for any
violation of such by LICENSEE or its Affiliates or Sublicensees, and that it
will defend and hold LICENSORS harmless in the event of any legal action of any
nature occasioned by such violation.

     10.6 Written notices required to be given under this Agreement shall be
addressed as follows:

     If to LICENSORS:                 Dr. Waldemar Gottardi
                                      Dr. Markus Nagl
                                      Institute for Hygiene and Social Medicine,
                                      Leopold-Franzens-Universitat
                                      Fritz-Pregl-Stra e 3
                                      A-6010 Innsbruck, Austria
                                      Telephone No.: +43 512 507 3430
                                      FacsimileNo.: +43 512 507 2070

     If to LICENSEE:                  Atlantic Technology Ventures, Inc.
                                      350 Fifth Avenue
                                      Suite 5507
                                      New York, NY 10118
                                      Telephone No.:  (212) 267-2503
                                      Facsimile No.:  (212) 267-2159

or such other address as either party may request in writing.

     10.7     Should a court of competent jurisdiction later consider any
provision of this Agreement to be invalid, illegal, or unenforceable, it shall
be considered severed provision, provided that the remaining provisions of this
Agreement are in accordance with the intention of the parties.

                                       10
<PAGE>

     10.8     (a)  In the event of any controversy or claim arising out of or
relating to any provision of this Agreement or the breach thereof, the parties
shall try to settle such conflicts amicably between themselves.  Subject to the
limitation stated in the final sentence of this section, 10.8, and any such
conflict which the parties are unable to resolve shall be settled through
binding arbitration conducted in accordance with the Rules of the Commercial
Arbitration of the International Chamber of Commerce by one or more arbiter(s)
knowledgeable in commercial law and practices, appointed in accordance with such
rules.

              (b)  The demand for arbitration shall be filed within a reasonable
time after the controversy or claim has arisen, and in no event after the date
upon which institution of legal proceedings based on such controversy or claim
would be barred by the applicable statue of limitation.  The arbitration shall
be in Innsbruck, Austria if initiated by LINCENSORS and New York, U.S.A. if
initiated by LICENSEE.

              (c)  At the request of either party, arbitration proceedings will
be conducted in the utmost secrecy; in such case, all documents, testimony and
records shall be received, heard and maintained by the arbitrator in the secrecy
under seal, available for the inspection only of the parties and their
respective attorneys and their respective experts who shall agree in advance and
in writing to receive all such information confidentially and to maintain such
information in secrecy until such information shall become generally known.

              (d)  The award through arbitration shall be final and binding.
Either party may enter any such award in a court having jurisdiction or may make
application to such court for judicial acceptance of the award and an order of
enforcement, as the case may be. Notwithstanding the foregoing, either party
may, without recourse to arbitration, assert against the other party a
third-party claim or cross-claim in any action brought by a third party, to
which the subject matter of this Agreement may be relevant.

     10.9     This Agreement constitutes the entire understanding between the
parties and neither party shall be obligated by any condition or representation
other than those expressly stated herein or therein or as may be subsequently
agreed to by the parties hereto in writing.

     10.10     This Agreement may be executed in identical counterparts, each of
which shall be deemed an original but all of which shall constitute one and the
same agreement.  This Agreement, once executed by a party, may be delivered to
the other party hereto by facsimile or transmission of a copy of this Agreement
bearing the signature of the party so delivering this Agreement.

                                       11
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized representatives.

The effective date of this Agreement is October 18, 2001.

Dr. Andreas Neher                        Dr. Waldemar Gottardi
/s/ Dr. Andreas Neher                    /s/ Dr. Waldemar Gottardi
--------------------------               --------------------------

                                         Dr. Markus Nagl
                                         /s/ Dr. Markus Nagl
                                         --------------------------

                                         Atlantic Technology Ventures, Inc.
                                         /s/ Frederic P. Zotos
                                         --------------------------
                                         By: Frederic P. Zotos, Esq.
                                         Its: CEO and President

                                       12
<PAGE>Exhibit 10.3

                              ASSIGNMENT AGREEMENT

     THIS  AGREEMENT  is  made  and entered into as of this 18th day of December
2002  ("Effective  Date")  by  and between ATLANTIC TECHNOLOGY VENTURES, INC., a
Delaware  corporation having offices at 350 Fifth Avenue, Empire State Building,
Suite  5507,  New  York,  New  York 10118 ("ATLANTIC"), and PATHOGENICS, LLC., a
Delaware limited liability corporation having offices at 534 Third Avenue, Suite
2,  New  York, NY 10016 ("PATHOGENICS"), and jointly owned by ATLANTIC employees
Frederic  P.  Zotos,  A.  Joseph  Rudick,  and  Michael  L.  Ferrari.

     WHEREAS,  ATLANTIC  is  party  to  a  certain  License  Agreement  for
N-Chlorotaurine  (NCT)  patent  applications entered on October 18, 2001 between
ATLANTIC  (as  exclusive, worldwide Licensee) and Drs. Waldemar Gottardi, Markus
Nagl,  and  Andreas  Neher  (collectively,  the  Licensor),  a  copy of which is
attached  hereto  as  Exhibit  A.

     WHEREAS, Atlantic owns all right, title, and interest in and to U.S. Patent
Application  Serial  No.  60/377,923,  entitled  "Method  for  Treating
Conjunctivitis",  and  filed on May 3, 2002 in the name of A. Joseph Ruddick and
Michael  L.  Ferrari.

     WHEREAS,  on  September  23,  2002  the  ATLANTIC board of directors held a
meeting  and  resolved  to  transfer  to  an  entity owned by ATLANTIC employees
Frederic  P.  Zotos,  A.  Joseph  Rudick,  and Michael L. Ferrari all ATLANTIC's
rights  to  the  NCT  technology  in  exchange for a 10% share of any milestone,
royalty  or other revenue generated by the NCT technology, a copy of the minutes
of  which  is  attached  hereto  as  Exhibit  B.

     WHEREAS,  PATHOGENICS  is  an  entity  jointly  owned by ATLANTIC employees
Frederic  P.  Zotos,  A.  Joseph  Rudick,  and Michael L. Ferrari and desires to
acquire,  and  ATLANTIC  is  willing  to assign to PATHOGENICS all of ATLANTIC's
rights  and  obligations  under the aforementioned License Agreement, and all of
ATLANTIC's  right,  title,  and  interest  in  and  to the aforementioned Patent
Application  and  any  inventions  described  therein.

     ACCORDINGLY,  for  good  and  valuable  consideration  described  below

     1.     ATLANTIC  hereby  assigns,  transfers,  conveys  and  relinquishes
exclusively to PATHOGENICS, its lawful successors and assigns, all of ATLANTIC's
rights  and obligations under the October 18, 2001 License Agreement, and all of
ATLANTIC's  right,  title, and interest in and to U.S. Patent Application Serial
No. 60/377,923 and any inventions described therein, as well as any other patent
applications  (U.S.  or  foreign)  directed  to  the subject matter thereof, all
patents  (U.S.  or  foreign)  that  may  be  granted  thereon  and all reissues,
reexaminations,  and extensions thereof, and all rights to claim priority on the
basis  of  such  Application  (collectively  the  "Patent Rights"), as fully and
entirely  as  the  same  would  have  been  held and enjoyed by ATLANTIC if this
assignment  had  not  been  made.

<PAGE>

     2.     PATHOGENICS  assumes, and agrees to pay and perform, all unperformed
obligations of ATLANTIC under the License Agreement.  PATHOGENICS agrees that by
executing  and delivering this Agreement PATHOGENICS shall become a party to the
License  Agreement  and agrees to be bound by all of the terms and provisions of
the  License  Agreement.

     3.     In consideration for the foregoing assignment, PATHOGENICS agrees to
pay  ATLANTIC  (or  its  lawful successors and assigns) ten percent (10%) of any
milestone,  royalty  or  other  revenue  received  by PATHOGENICS (or its lawful
successors  and  assigns) from the sale or sublicensing of the License Agreement
or  from  the  sale  or  licensing  of  the  Patent  Rights.

     4.     ATLANTIC  shall  execute  and  deliver to PATHOGENICS the recordable
Assignment  attached  as  Exhibit  C  hereto,  and,  from time to time after the
Effective  Date  hereof upon the request of PATHOGENICS, such further conveyance
instruments as may be necessary or desirable to evidence more fully the transfer
of  ATLANTIC's  rights  and  obligations  under the License Agreement and to the
Patent  Rights.  ATLANTIC further agrees to provide testimony in connection with
any  proceeding  affecting  the foregoing rights and obligations, and to perform
any  other  acts  deemed  necessary  to  carry out the intent of this Agreement.
PATHOGENICS  shall  reimburse ATLANTIC for any and all costs reasonably incurred
by  ATLANTIC  in  performance  under  this  paragraph.

     5.     In furtherance of this Agreement, ATLANTIC hereby acknowledges that,
from  the Effective Date forward, PATHOGENICS has succeeded to all of ATLANTIC's
rights,  obligations,  title,  and standing in relation to the Patent Rights, to
institute  and  prosecute  all  suits  and proceedings, to take all actions that
PATHOGENICS,  in  its  sole discretion, may deem necessary or proper to collect,
assert,  or  enforce  any  claim,  right,  or title of any kind under the Patent
Rights,  whether  arising  before  or  after  the  Effective Date, to defend and
compromise  any  and  all  such  actions, suits, or proceedings relating to such
transferred  and  assigned  rights, title, interest, and benefits, and to do all
other  such  acts  and  things  in  relation  thereto as PATHOGENICS in its sole
discretion  deems  advisable.

     6.     ATLANTIC  represents  and  warrants  that  it  has obtained from the
Licensor  the  required consent to assignment of the License Agreement, which is
embodied  in  the  letter  attached  hereto  as  Exhibit  D.

     7.     ATLANTIC  represents  and  warrants  that, to the best of ATLANTIC's
knowledge,  upon consummation of this Agreement, PATHOGENICS shall have good and
marketable  title  to  the  Patent  Rights, free and clear of any and all liens,
mortgages,  encumbrances,  pledges,  security interests, licenses, or charges of
any  nature  whatsoever.

     8.     This  Agreement  shall inure to the benefit of, and be binding upon,
the  parties  hereto  together  with  their  respective  legal  representatives,
successors  and  assigns.

     9.     This Agreement shall be governed by and construed in accordance with
the  laws of the State of New York (excluding conflicts of law rules) and of the
United  States  of  America.

                                        2
<PAGE>

     10.     This  Agreement merges and supersedes all prior and contemporaneous
agreements, assurances, representations, and communications between or among the
parties  hereto  concerning  the  matters  set  forth  herein.

     11.     If  a  dispute  arises  out  of  or relates to this Agreement, or a
breach  thereof,  and  if the dispute cannot be settled through negotiation, the
parties  agree  to  first  try  in good faith to settle the dispute by mediation
administered  by  the  American  Arbitration  Association  under  its Commercial
Mediation  Rules  before  resorting  to  arbitration,  litigation, or some other
dispute  resolution  procedure.

     12.     Any  claim  or  controversy  arising  out  of  or  relating to this
Agreement, or the breach thereof, that cannot be settled through mediation shall
be  settled  by arbitration administered by the American Arbitration Association
under its Commercial Arbitration Rules, and judgment o the award rendered by the
arbitrator  may  be  entered  in  any  court  having  jurisdiction  thereof.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement the day
and  year  first  written  above.

ATLANTIC  TECHNOLOGY  VENTURES,  INC.          PATHOGENICS  LLC.

By:  /s/ Frederic  P.  Zotos                  By: /s/ Frederic  P.  Zotos
     ---------------------------                    --------------------------

Name:  Frederic  P.  Zotos,  Esq.              Name:  Frederic  P.Zotos, Esq.
Title:  President  &  CEO                      Title:  Managing  Member
Date: 12/18/02                                 Date: 12/18/02

WITNESS

By:  /s/ Sarah E. Laut
     ----------------------------
Witness:  Sarah E. Laut
Date: 12/18/02

                                        3
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]